Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock
Los Gatos, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq:ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,000,000 shares of the Company’s common stock at a purchase price of $0.38 per share in a registered direct offering. The closing of the offering is expected to occur on or about March 16, 2023, subject to the satisfaction of customary closing conditions.
Related news for (ARDS)
- Aridis Provides Corporate Update
- Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
- Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
- Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
- Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV